Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

UroGen Pharma (URGN) Equity Ratio: 2016-2025

Historic Equity Ratio for UroGen Pharma (URGN) over the last 9 years, with Sep 2025 value amounting to -0.62.

  • UroGen Pharma's Equity Ratio fell 838.05% to -0.62 in Q3 2025 from the same period last year, while for Sep 2025 it was -0.62, marking a year-over-year decrease of 838.05%. This contributed to the annual value of -0.03 for FY2024, which is 91.58% up from last year.
  • According to the latest figures from Q3 2025, UroGen Pharma's Equity Ratio is -0.62, which was down 39.41% from -0.45 recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Equity Ratio registered a high of 0.79 during Q1 2021, and its lowest value of -1.45 during Q2 2023.
  • Its 3-year average for Equity Ratio is -0.40, with a median of -0.22 in 2023.
  • As far as peak fluctuations go, UroGen Pharma's Equity Ratio crashed by 1,037.86% in 2022, and later skyrocketed by 138.96% in 2024.
  • UroGen Pharma's Equity Ratio (Quarterly) stood at 0.07 in 2021, then crashed by 1,037.86% to -0.66 in 2022, then skyrocketed by 44.50% to -0.37 in 2023, then surged by 91.58% to -0.03 in 2024, then slumped by 838.05% to -0.62 in 2025.
  • Its last three reported values are -0.62 in Q3 2025, -0.45 for Q2 2025, and -0.19 during Q1 2025.